Cranbury Forum | Bulletin | Info Sharing Â
[Click here to bookmark this page: http://cranbury.info]
â–ª
Cranbury School
â–ª
Cranbury Township
â–ª
Cranbury Library
â–ª
Cranbury.org
â–ª
Cranburyhistory.org
(Press Ctrl and = keys to increase font size)
Search
Register (optional)
Log in to check your private messages
Log in
[http://cranbury.info]
->
News | Events
Post a reply
Username
Subject
Message body
Emoticons
Font colour:
Default
Dark Red
Red
Orange
Brown
Yellow
Green
Olive
Cyan
Blue
Dark Blue
Indigo
Violet
White
Black
Font size:
Tiny
Small
Normal
Large
Huge
Close Tags
Options
HTML is
ON
BBCode
is
ON
Smilies are
ON
Disable HTML in this post
Disable BBCode in this post
Disable Smilies in this post
All times are GMT - 4 Hours
Jump to:
Select a forum
Topics
----------------
News | Events
School | Parenting
Blogs by Cranbury Residents
Shopping | Good Deals | Price Talk
Home Sweet Home
House For Sale
Home Sales Pricing Records
Financial | Stocks | Mutual Funds
Cool Bytes & Bits
Garage Sale | ForSale Ads | Things to Trade
Tech Related (PC, Internet, HDTV, etc.)
Interesing and Fun Stuff to Share
What's Your Favorite?
Interests | Hobbies
Cranbury History
Radom Thoughts | Sports | Kitchen Sink
Amazon Deals
Local Business Info
----------------
Local Business Ads (FREE)
Support
----------------
Daily Sponsored Message & Amazon Ads
About Us | Your Privacy | Suggestion | Sponsored
Test Area (Practice your posting skills here)
Topic review
Author
Message
Cranbury Company
Posted: Thu, Sep 25 2008, 4:51 pm EDT
Post subject: Ligand May Pay as Much as $70M for Pharmacopeia
Posted date: 9/24/2008
Ligand May Pay as Much as $70M for Pharmacopeia
San Diego-based Ligand Pharmaceuticals Inc., developer of the painkiller Avinza, said Sept. 24 it would buy Pharmacopeia of Cranbury, N.J. in a stock deal valued as high as $70 million.
“The acquisition of Pharmacopeia will complement and accelerate our product development programs, strengthen our research capability and increase our potential royalty streams,” Ligand Chief Executive John Higgins said in a statement.
Under the terms of the deal, Ligand will issue 58 cents a share for each outstanding Pharmacopeia share, giving Ligand shareholders 84 percent control of the company.
Additionally, Ligand stockholders would be entitled to an additional $15 million on milestone agreements related to one of Pharmacopeia’s drug development programs.
The combined company is projected to have about $90 million in cash at the time of closing.
The merger is expected to close by the first quarter of 2009 and is subject to regulatory clearance and stockholder approval.
Ligand trades on the Nasdaq under the symbol LGND. Shares closed Sept. 24 at $3.12.
— Heather Chambers
http://www.sdbj.com/industry_article.asp?aID=58680267.7694361.1685905.5136334.1232656.205&aID2=129676